BioView 2025: Abbott Holds, Asia Shrinks, and Funding Is Still the Bottleneck

Company Introduction

At first glance, BioView can look like another small biotech name built around liquid-biopsy promise. That is only a partial read. As of the end of 2025, the company's economics still rest first on selling and servicing imaging and scanning systems for abnormal-cell detection, not on a commercial liquid-biopsy product. This is a medical-device business with an installed base, service contracts, upgrades, and a North American sales and support arm through the US subsidiary. Liquid biopsy remains strategic optionality, not the current profit engine.

What is actually working now? The North American core is still holding. Revenue in North America was NIS 12.8 million, down only 4.9%, and service-contract revenue declined just 6.5% to NIS 9.7 million. At the same time, Abbott contributed NIS 5.45 million, equal to 27% of sales, versus only 14% in 2024. So even in a weak year, the company still has a real commercial base that keeps part of the business alive.

What is not working? The bottleneck is funding flexibility, not only sales. Total revenue fell 22.3% to NIS 19.9 million, Asia dropped 79.2% to NIS 1.17 million, systems sold fell to 14 from 19, and gross profit declined to NIS 9.5 million. Gross margin fell to 47.8% from 60.7%, even though service contracts already made up 48.8% of sales. That matters because the mix looked better mainly because system and upgrade revenue weakened faster, not because the company suddenly reached a cleaner recurring-revenue model.

That is also what a superficial reader can miss. It is easy to focus on the service-heavy mix, the AI development push, the post-balance-sheet Sanmed renewal, and the Inspira transaction attempt around the liquid-biopsy business. But under that layer sit a NIS 5.4 million deferred-tax-asset write-off, a NIS 1.0 million liability tied to adjustment shares, cash down to NIS 4.9 million, and a NIS 1.0 million bank draw after the balance-sheet date. The story is still not clean.

There is also a practical constraint at the stock level. Short interest is negligible, so this is not a story driven by technical pressure from shorts. On the other hand, Emmanuel Gil signed an agreement at the end of December 2025 to sell all of his holdings, 27.75 million shares, in staged transactions over 12 months. That means even if operations stabilize, the market still has to digest a meaningful overhang of supply.

The economic map at the end of 2025 looked like this:

The implication is that the BioView of late 2025 is not a clean growth company, but it is also not only a conceptual shell. It still has a real core of systems, services and customers. The problem is that this core is not yet strong enough to comfortably fund the development agenda, the strategic narrative, and a safe balance-sheet buffer at the same time.

Events And Triggers

The first trigger: Asia nearly disappeared, and Sanmed was renewed only after year end

The clearest weakness in 2025 was Asia. Revenue in the region fell to NIS 1.17 million from NIS 5.61 million in 2024 and NIS 12.54 million in 2023. At the same time, Sanmed, which represented 20% of revenue in 2024 and 29% in 2023, disappeared from the list of major customers in 2025. This is not just a geographic datapoint. It means the external channel that was supposed to support broader commercialization simply did not deliver this year.

The nuance matters. The company did renew the distribution agreement with Sanmed on March 8, 2026 for another two years, and the customer section notes that about 100 systems have been sold to Sanmed to date. But a renewed agreement is not the same thing as renewed demand. The market will now look for actual orders, not just renewed intent.

The second trigger: the Inspira route tried to solve liquid-biopsy funding and did not close

On January 5, 2026, the company signed a non-binding memorandum of understanding to sell its liquid-biopsy activity to a Nasdaq-listed counterparty in exchange for up to 40% of that party's fully diluted equity, subject to a third-party investment of about $15 million into the counterparty. At the same time, a binding $1 million convertible-loan agreement was signed, carrying 10% annual interest and a set of conditions precedent including exchange approval and a separate $5 million third-party investment.

The important part is what happened next. On February 19, 2026, an amendment extended the deadline for satisfying the conditions by 30 days. On March 22, 2026, the company announced that the period expired, the conditions were not met, and the parties were no longer in discussions regarding the transaction. In other words, the route that tried to move the liquid-biopsy activity out of a small Israeli balance sheet and into a better-funded US vehicle did not mature.

That is not a footnote. The liquid-biopsy activity discussed in that transaction includes the company's intellectual property and the activity with Angle around a blood test for breast-cancer cells. When a transaction like that fails, the company does not only miss a strategic option. It remains with the same old challenge: how to fund the option without putting more strain on the listed company that still holds it.

The third trigger: three private placements bought time, but also added a dilution mechanism

During 2025, the company completed three private placements at NIS 0.30 per share for total gross proceeds of NIS 2.85 million. Alongside those raises, each deal included an adjustment-share mechanism if the average share price in the ten trading days before the check date comes in below NIS 0.30. By year end, the company had already recognized a NIS 1.036 million liability tied to those adjustment shares, and a NIS 1.036 million financing expense was recorded from the fair-value remeasurement.

This matters for two reasons. First, 2025 bought a bit of cash time, but at the cost of a more complicated equity structure. Second, the market has not closed this issue. On April 6, 2026, the stock traded at NIS 0.165, well below the NIS 0.30 reference level in the placements, so the adjustment-share mechanism remains highly relevant to forward dilution expectations.

The fourth trigger: both management and the cost base are changing midstream

On January 29, 2026, the company announced that Elad Kfir would step down as vice president of marketing and sales effective March 18, 2026, and on March 5, 2026 it appointed Hagai Langbeheim to the role. This is happening exactly while the company needs to stabilize Asia, hold Abbott, and improve the conversion of development into revenue.

At the same time, the company is also changing its cost base. Efficiency measures were completed in September 2025, and in October 2025 the office lease was amended so that 476 square meters would be given up starting March 1, 2026. These are sensible steps, but they also show that the company is no longer operating as if 2026 were a clean growth year. It is operating like a company trying to buy time.

Efficiency, Profitability And Competition

The service base is holding, but the higher mix share is not the same as higher-quality growth

The key number for understanding 2025 is not only the drop in revenue, but the shape of the drop. Revenue from systems fell 29.5% to NIS 6.55 million. Hardware, software and other upgrades fell 38.7% to NIS 3.67 million. By contrast, service-contract revenue fell only 6.5% to NIS 9.72 million. That is why the service share of revenue rose to 48.8% from 40.5% in 2024.

On one hand, that is evidence that the installed base is still working. The company still sells service, support and licenses even in a weak year. On the other hand, this is not the same quality of growth that would have come from actual service expansion. Here, service held up better, but the mix improvement mainly reflects how much faster new sales weakened.

Even after cutting R&D, the cost base is still too heavy

The company did try to adjust expenses. Net R&D expense fell 29.4% to NIS 4.70 million. Professional services within R&D, mainly subcontractors, fell to NIS 430 thousand from NIS 2.10 million. The employee count fell to 31 at year end from 33 a year earlier, and by the report date the group employed 29 full-time staff plus two part-time employees.

But on the other side of the equation, sales and marketing expense actually rose 4.5% to NIS 5.64 million, and general and administrative expense rose 7.7% to NIS 6.98 million. That is why operating loss widened to NIS 7.82 million from NIS 2.88 million. In other words, BioView still carries an expense platform that was built for a broader commercial scale than the year actually delivered.

There is still a first sign of stabilization. On a half-year split, the second half of 2025 produced NIS 10.66 million of revenue versus NIS 9.27 million in the first half, and gross profit rose to NIS 5.31 million from NIS 4.20 million. Operating loss also narrowed to NIS 2.83 million from NIS 4.99 million. This is not a turnaround, but it does suggest the core has not completely broken.

The accounting write-down and FX pressure told a deeper story

Another non-obvious point is that the bottom line worsened not only because activity was weak. During 2025, the US dollar weakened 12.5% against the shekel, and the company explicitly says this hurt results because sales are denominated in dollars while the accounts are presented in shekels. The sensitivity analysis shows that if the group's functional currency had weakened by 10% against the dollar, the after-tax loss would have been about NIS 502 thousand smaller.

That was compounded by another accounting hit. Net finance expense rose to NIS 1.324 million, from almost zero in 2024, mainly because of the NIS 1.036 million remeasurement of the adjustment-share liability. In addition, the company wrote off NIS 5.407 million of deferred tax assets in 2025 after concluding that utilization was no longer expected. This is non-cash, but it does say something important: the company is no longer willing to show full accounting confidence in generating enough taxable profit in the near term.

This is also where competition matters. The company operates against players such as MetaSystems, Leica BioSystems and Applied Spectral Imaging, now owned by ZYTOMICS. Some of them are larger and have deeper development and commercial resources. So when BioView enters a year of tighter spending, funding pressure and commercial reorganization, it does so against competitors that do not necessarily need to contract along with it.

Cash Flow, Debt And Capital Structure

The right frame here is all-in cash flexibility

In BioView's case, the right frame is all-in cash flexibility rather than normalized cash generation. The reason is simple: the real question is not only how much the business produces before discretionary uses, but how much room remains after actual cash uses.

In 2025, cash and cash equivalents fell to NIS 4.92 million from NIS 8.22 million. In addition, the company held NIS 2.30 million of marketable securities, so relatively available liquidity stood at about NIS 7.2 million before a restricted deposit of NIS 312 thousand. That is not an immediate distress picture, but it is also not a comfortable cushion for a company that continues to develop, market and search for a strategic route for liquid biopsy.

Operating cash flow did not collapse, but it was helped by working-capital release

Operating cash flow was negative NIS 3.06 million, roughly in line with the negative NIS 3.11 million in 2024. On the surface, that looks like stabilization. But what matters is how the company got there. In 2025, receivables released NIS 2.69 million of cash and inventory released another NIS 2.01 million. At the same time, deferred revenue declined by NIS 565 thousand and other balances, including warranty provisions, consumed NIS 1.45 million.

So part of the apparent cash relief came from shrinking receivables and inventory, not from a return to profitability. That also fits the working-capital metrics: customer credit days fell to 59 from 92, average customer credit fell to NIS 3.24 million, and inventory days improved to 252 from 264. The improvement is welcome, but it is also part of a picture of lower commercial scale.

The balance sheet is still positive, but flexibility depends on the bank and the market

As of December 31, 2025, the company still showed positive working capital of NIS 7.55 million and positive equity of NIS 9.42 million. Current liabilities totaled NIS 8.60 million, including NIS 3.04 million of deferred revenue, a NIS 1.04 million fair-value financial liability, and about NIS 3.04 million of trade and other payables. Lease liabilities totaled NIS 2.79 million, of which NIS 1.30 million were current.

The critical part sits after the balance-sheet date. On March 18, 2026, the company drew NIS 1 million from a NIS 3.5 million bank credit line in the form of a monthly renewable On Call loan bearing 7.3% annual interest, secured by the marketable-securities portfolio. This is not a catastrophic move. But it is also not the move of a company whose funding story is already solved. It is a time-buying loan.

On top of that, inventory still stood at NIS 6.07 million, including an inventory write-down of NIS 810 thousand versus NIS 268 thousand the year before. So even after inventory came down, there is still a relatively heavy support and component stock versus the size of the activity, and that stock has already produced a meaningfully larger write-down.

Outlook

Finding one: the higher service mix does not solve the problem if it comes together with a collapse in systems and Asia.

Finding two: there was some operating improvement in the second half of 2025, but the bottom line was blown out by non-cash write-downs and financing-linked equity liabilities.

Finding three: the Inspira route showed that the company itself understands the liquid-biopsy activity needs a stronger funding home, but for now that route has closed without a deal.

Finding four: 2026 will not be judged only on development progress, but on whether cost actions, commercial management changes and the Sanmed renewal finally translate into stability.

That leads to the core conclusion for the coming year: 2026 is a double proof year, commercial and financial. Commercial, because the company itself presents a development plan that includes new applications, an Encore configuration for 120 slides, new CTC applications with Angle, and AI algorithms. Financial, because all of that still has to happen with a limited cash cushion, a bank line that was already used after year end, and without the Inspira transaction that was supposed to move liquid biopsy onto a different track.

What has to happen in the core business? First, North America and Abbott need to keep holding the base. Without that, the company will remain with a commercial core that is too small relative to the fixed-cost structure. After that, the Sanmed renewal has to turn into orders, not just a contract. And the company needs to show that the efficiency actions, including the smaller office footprint and the temporary salary reductions applied to several senior managers, actually show up in the 2026 expense line.

What has to happen in liquid biopsy? Either the company finds a funded partner, or it runs the activity much more narrowly. The filing itself keeps pointing to the potential in CTC and liquid biopsy. That is true at the option level. But without a proven commercial engine or a stronger funding home, that option can continue to consume management bandwidth and cash.

What can change the market's interpretation in the short to medium term? Three things. First, a real sign that Asia is ordering again. Second, a filing showing that operating loss continues to narrow without help from one-off working-capital release. Third, the absence of a need for another urgent funding solution beyond the bank facility that was already drawn in March 2026.

Risks

Customer concentration and reliance on a few channels

In 2025, Abbott already accounted for 27% of sales. In 2024, Sanmed accounted for 20%, and in 2025 it nearly vanished. That shows two problems at once: when a channel works, there is something to lean on, and when it weakens, the hit is sharp. The company has other customers, but the identities of Abbott and Sanmed materially shape the business.

Funding risk and dilution risk

The company still reports positive working capital, but it is clearly in a place where every funding move matters. The adjustment shares, the bank line, and the fact that the Inspira transaction did not close all leave the funding question open. This does not have to end in another dilutive raise, but it is not off the table either.

FX and regulatory risk

Most customers are dollar-linked, and the company also has a meaningful US activity layer. The sharp dollar weakness in 2025 already hurt results. In addition, the company continues to operate in a world shaped by FDA, CE, NMPA and MFDS approvals, while the liquid-biopsy effort depends both on regulatory and commercialization progress.

Suppliers and inventory

The company acknowledges a degree of dependence on microscope and stage suppliers, and explicitly says that qualifying a new supplier would require meaningful resources. At the same time, the inventory write-down rose sharply. For a small company running service and support inventory, any demand misread can keep weighing on profitability.

Conclusions

BioView ends 2025 as a company with a real core, but not enough room. Abbott and the North American business are still holding the base together, and service contracts show that the installed systems continue to generate revenue. The central bottleneck remains funding: Asia shrank, the Inspira route did not close, and the balance sheet is still buying time rather than providing strategic freedom.

Current thesis: BioView currently relies on an existing service and sales base that is enough to keep the core alive, but still not enough to comfortably fund the strategic liquid-biopsy option.

What changed versus the previous read? The US base looks more stable than the headline revenue decline suggests, but Asia is no longer delivering the growth tail, and through the deferred-tax write-off and the funding moves the company is effectively admitting that it is still far from clean and sustainable profitability.

The strongest counter-thesis is that the market is being too harsh on one weak year in Asia, and that the Sanmed renewal, operating efficiency actions, and the sales-management change can be enough to return the company to a more stable path already in 2026.

What can change the market interpretation in the short to medium term? Renewed orders through Sanmed, continued stability through Abbott, a filing showing that operating loss is narrowing without one-off help from working capital, and most of all a sign that the company does not quickly need another funding fix.

Why does this matter? Because BioView is no longer only a technology question. It is a question of whether technological value can be carried through a small listed company without being worn down by dilution, inventory and endless waiting for the next strategic transaction.

Over the next 2 to 4 quarters, the thesis strengthens if Abbott keeps holding the base, Sanmed starts ordering again, and the cost cuts finally show up in the operating line. It weakens if Asia keeps stalling, if liquid-biopsy optionality keeps consuming resources without a clearer funding route, or if the company has to add another layer of dilution before the core stabilizes.